Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC1416 in Moderate to Severe COPD
NCT07402551Phase 2Recruiting
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing RC1416 Injection with Placebo Control (2 arms). Primary endpoints: Annualized rate of moderate or severe COPD exacerbations at 52 weeks and Forced Expiratory Volume in 1 Second at 52 weeks. Started Mar 2026; status: recruiting.
02
Drugs
RC1416
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07402551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07402551.